help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Iervasi, G.
Right arrow Articles by Donato, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Iervasi, G.
Right arrow Articles by Donato, L.
The Journal of Clinical Endocrinology & Metabolism Vol. 82, No. 3 884-888
Copyright © 1997 by The Endocrine Society


Experimental Studies

Evidence That Atrial Natriuretic Peptide Tissue Extraction Is Not Changed by Large Increases in Its Plasma Levels Induced by Pacing in Humans

G. Iervasi, A. Clerico, A. Pilo, F. Vitek, S. Berti, C. Palmieri, M. Ravani, L. Sabatino, C. Manfredi, M. G. Del Chicca, A. Biagini and L. Donato

Laboratory of Cardiovascular Endocrinology, CNR Institute of Clinical Physiology, Pisa, Italy; and the Institute of Biophysics, First Medical Faculty, Charles University (F.V.), Prague, Czech Republic

Address all correspondence and requests for reprints to: G. Iervasi, M.D., CNR Institute of Clinical Physiology, Via Savi 8, 56100 Pisa, Italy. E-mail: iervasi{at}nsifc.ifc.pi.cnr.it (Dr. Giorgio

Atrial natiurectic peptide (ANP) is a cardiac hormone with a very short plasma half-life, which plays an important role in a variety of clinical conditions associated with an increase in pressure and/or volume overload on the heart. The MCR of the hormone is considered to represent a stable parameter, reflecting the uptake and degradation rate of ANP by the periphery, only scarcely affected by rapid oscillations of circulating levels. To evaluate the extent to which MCR is affected by rapid and large variations of circulating levels of the hormone, we measured MCR in five patients with different degrees of myocardial function (from normal to severely impaired), in whom changes in ANP levels were induced by atrial and/or ventricular pacing. Cardiac output was simultaneously measured by thermodilution to calculate whole body extraction of ANP. During constant iv infusion of [125I]ANP, the hormone MCR was determined both under basal conditions (at tracer equilibration, 20–30 min after the start of infusion) and during atrial and ventricular pacing. Pacing maneuvers, begun 50 min after the start of infusion, induced a marked and rapid increase in endogenous plasma ANP values in all patients (on the average, 3.7-fold compared to basal values; range, 1.8–5.68), whereas corresponding values of [125I]ANP only minimally changed. The MCR of ANP (3.62 ± 1.06 L/min, mean ± SD) slightly decreased (by repeated measures ANOVA, P = 0.0458) during atrial and ventricular pacing procedures (3.35 ± 1.03 and 3.15 ± 0.74 L/min, respectively), reaching a mean value of 88.7 ± 9.0% compared to basal. The small decrease in MCR could be almost completely ascribed to hemodynamic factors; indeed, basal cardiac output (5.76 ± 1.70 L/min) was found, on the average, to be slightly decreased during atrial and ventricular pacing (5.28 ± 1.46 and 5.16 ± 1.33 L/min, respectively), and so whole body extraction of the hormone, measured before pacing (50.0 ± 12%), remains stable throughout the study period (50.4 ± 10.6% and 49.6 ± 10% during atrial and ventricular pacing, respectively). Our findings demonstrate that degradative mechanisms involved in ANP clearance are not saturable at least for acute elevations of ANP plasma levels up to 3–5 times the basal level.




This article has been cited by other articles:


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
R. L. Woods
Vasoconstrictor actions of atrial natriuretic peptide in the splanchnic circulation of anesthetized dogs
Am J Physiol Regulatory Integrative Comp Physiol, December 1, 1998; 275(6): R1822 - R1832.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
G. Iervasi, A. Clerico, A. Pilo, L. Sabatino, C. Manfredi, F. Forini, M. G. Del Chicca, C. Palmieri, M. Ravani, and L. Donato
Atrial Natriuretic Peptide Is Not Degraded by the Lungs in Humans
J. Clin. Endocrinol. Metab., August 1, 1998; 83(8): 2898 - 2906.
[Abstract] [Full Text]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
A. Pilo, G. Iervasi, A. Clerico, F. Vitek, S. Berti, C. Palmieri, A. Biagini, and L. Donato
Circulatory model in metabolic studies of rapidly renewed hormones: application to ANP kinetics
Am J Physiol Endocrinol Metab, March 1, 1998; 274(3): E560 - E572.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1997 by The Endocrine Society